Compare Deutsche Bank AG (DB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Inovio Pharmaceuticals Inc — how do they compare? Deutsche Bank AG trades at $33.64 (market cap $63.13B), while Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M). The key difference: Deutsche Bank AG is far larger — about 528.6× Inovio Pharmaceuticals Inc's market cap, and Deutsche Bank AG pays a 3.47% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DB | INO | |
|---|---|---|
Market Cap | $63.13B | $119.42M |
Volume | 3,260,488 | 2,789,649 |
Sector | Financials | Health |
52-Week High | $41.56 | $2.65 |
52-Week Low | $28.37 | $0.66 |
Typical Hold Time | 80 Days | 43 Days |
Enterprise Value | $75.71B | $90.75M |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.63, down 4.27% amid a bearish technical signal. The stock shows attractive valuation with a P/E of 9.1 and P/B of 0.71, while recent earnings beat expectations in two of the last three quarters. Net income surged to $6.93B in 2025, though Q3 2026 investment bank revenue is expected flat to slightly down. Cash flow improved significantly with net cash flow of $7.61B in 2025.
The outlook is mixed: strong fundamentals and low valuation support upside, but bearish technicals and cautious analyst consensus (57.58% hold) indicate near-term headwinds. Key risks include revenue volatility in investment banking and macroeconomic sensitivity. The stock offers value potential if execution on 2028 targets holds.
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
